Terms: = Liver cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Clinical Outcome
17 results:
1. MUC1 triggers lineage plasticity of her2 positive mammary tumors.
Pang Z; Dong X; Deng H; Wang C; Liao X; Liao C; Liao Y; Tian W; Cheng J; Chen G; Yi H; Huang L
Oncogene; 2022 May; 41(22):3064-3078. PubMed ID: 35461328
[TBL] [Abstract] [Full Text] [Related]
2. Complete Remission of Metastatic her2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment.
Gutting T; Schulte N; Belle S; Betge J; Härtel N; Wilke J; Weers J; Ebert MP; Zhan T
J Gastrointestin Liver Dis; 2019 Dec; 28(4):503-507. PubMed ID: 31826054
[TBL] [Abstract] [Full Text] [Related]
3. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/her2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
[TBL] [Abstract] [Full Text] [Related]
4. Genomic Profiling of Biliary Tract cancers and Implications for clinical Practice.
Jain A; Kwong LN; Javle M
Curr Treat Options Oncol; 2016 Nov; 17(11):58. PubMed ID: 27658789
[TBL] [Abstract] [Full Text] [Related]
5. Pattern of metastasis and outcome in patients with breast cancer.
Gerratana L; Fanotto V; Bonotto M; Bolzonello S; Minisini AM; Fasola G; Puglisi F
Clin Exp Metastasis; 2015 Feb; 32(2):125-33. PubMed ID: 25630269
[TBL] [Abstract] [Full Text] [Related]
6. HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver.
Lédel F; Stenstedt K; Hallström M; Ragnhammar P; Edler D
Acta Oncol; 2015 Apr; 54(4):480-6. PubMed ID: 25601452
[TBL] [Abstract] [Full Text] [Related]
7. clinical outcome in women with her2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract] [Full Text] [Related]
8. clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
[TBL] [Abstract] [Full Text] [Related]
9. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract] [Full Text] [Related]
10. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype.
Yi SY; Ahn JS; Uhm JE; Lim DH; Ji SH; Jun HJ; Kim KH; Chang MH; Park MJ; Cho EY; Choi YL; Park YH; Im YH
BMC Cancer; 2010 Oct; 10():527. PubMed ID: 20920367
[TBL] [Abstract] [Full Text] [Related]
11. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit.
Brunetto AT; Sarker D; Papadatos-Pastos D; Fehrmann R; Kaye SB; Johnston S; Allen M; De Bono JS; Swanton C
Br J Cancer; 2010 Aug; 103(5):607-12. PubMed ID: 20664586
[TBL] [Abstract] [Full Text] [Related]
12. Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Schoppmeyer K; Frühauf N; Oldhafer K; Seeber S; Kasimir-Bauer S
Oncol Rep; 2006 Feb; 15(2):449-54. PubMed ID: 16391868
[TBL] [Abstract] [Full Text] [Related]
13. Re-evaluation of her2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab.
Stemmler HJ; Stieber P; Lässig D; Heinemann V
Onkologie; 2005 Feb; 28(2):95-7. PubMed ID: 15692222
[TBL] [Abstract] [Full Text] [Related]
14. Small-cell carcinoma of the urinary bladder. A clinico-pathological study of ten cases.
Soriano P; Navarro S; Gil M; Llombart-Bosch A
Virchows Arch; 2004 Sep; 445(3):292-7. PubMed ID: 15248064
[TBL] [Abstract] [Full Text] [Related]
15. Evaluation of sICAM-1, sVCAM-1, and sE-Selectin levels in patients with metastatic breast cancer receiving high-dose chemotherapy.
Bewick M; Conlon M; Lee H; Parissenti AM; Zhang L; Glück S; LaFrenie RM
Stem Cells Dev; 2004 Jun; 13(3):281-94. PubMed ID: 15186724
[TBL] [Abstract] [Full Text] [Related]
16. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel.
Barozzi C; Ravaioli M; D'Errico A; Grazi GL; Poggioli G; Cavrini G; Mazziotti A; Grigioni WF
Cancer; 2002 Feb; 94(3):647-57. PubMed ID: 11857296
[TBL] [Abstract] [Full Text] [Related]
17. Determination of the oncogenes p53 and c-erb B2 in the tumour cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time.
Heinze T; Jonas S; Kärsten A; Neuhaus P
Anticancer Res; 1999; 19(4A):2501-3. PubMed ID: 10470182
[TBL] [Abstract] [Full Text] [Related]
